Peace of mind for biomolecule analysis
Shimadzu has introduced the new “Nexera Bio” solution, a biocompatible Ultra-High Performance Liquid Chromatography (UHPLC) system. It offers the same superior reliability, robustness and expandability as other Nexera series UHPLC systems. It is particularly well suited for analyzing protein-based pharmaceuticals, antibody drugs and other substances developed or manufactured using biotechnologies. The Nexera Bio is compatible with mobile phase solvents containing high concentrations of salts or acids, and has also been designed to inhibit peak tailing caused by adsorption to tubing. The Nexera Bio is equipped with new and advanced product features such as maximum corrosion resistance, low surface activity and minimized sample loss.
The new “Nexera Bio” solution, the biocompatible Ultra-High Performance Liquid Chromatography (UHPLC) system of Shimadzu
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
